title: Platelet surface expression of SDF-1 is associated with clinical outcomes in the patients with cardiovascular disease.
abstract: Platelet surface expression levels of stromal cell derived factor 1 (SDF-1) are elevated in acute coronary syndrome and associated with LVEF% improvement after myocardial infarction (MI). Platelet SDF-1 might facilitate thrombus formation and endomyocardial expression of SDF-1 is enhanced in inflammatory cardiomyopathy and positively correlates with myocardial fibrosis. The influence of platelet SDF-1 on outcome in the patients with symptomatic coronary artery disease (CAD) is to the best of our knowledge unknown. Blood samples of 608 consecutive CAD patients were collected during the percutaneous coronary intervention and analyzed for surface expression of SDF-1 by flow cytometry. The primary combined endpoint was defined as the composite of either MI, or ischemic stroke, or all-cause death. Secondary endpoints were defined as the aforementioned single events. The patients with baseline platelet SDF-1 levels above the third quartile showed a significantly worse cumulative event-free survival when compared to the patients with lower baseline SDF-1 levels (first to third quartile) (log rank 0.009 for primary combined endpoint and log rank 0.016 for secondary endpoint all-cause death). Multivariate Cox regression analysis showed that SDF-1 levels above the third quartile were independently associated with the primary combined endpoint and the secondary endpoint all-cause death. We provide first clinical evidence that high platelet expression levels of SDF-1 influence clinical outcomes in CAD patients in a negative way.
authors.affiliation: a Medizinische Klinik III, Kardiologie und Kreislauferkrankungen , University Tübingen , Tübingen , Germany.
authors.forename: Dominik
authors.initials: D
authors.lastname: Rath
authors.affiliation: a Medizinische Klinik III, Kardiologie und Kreislauferkrankungen , University Tübingen , Tübingen , Germany.
authors.forename: Madhumita
authors.initials: M
authors.lastname: Chatterjee
authors.affiliation: a Medizinische Klinik III, Kardiologie und Kreislauferkrankungen , University Tübingen , Tübingen , Germany.
authors.forename: Angela
authors.initials: A
authors.lastname: Bongartz
authors.affiliation: a Medizinische Klinik III, Kardiologie und Kreislauferkrankungen , University Tübingen , Tübingen , Germany.
authors.forename: Karin
authors.initials: K
authors.lastname: Müller
authors.affiliation: a Medizinische Klinik III, Kardiologie und Kreislauferkrankungen , University Tübingen , Tübingen , Germany.
authors.forename: Michal
authors.initials: M
authors.lastname: Droppa
authors.affiliation: a Medizinische Klinik III, Kardiologie und Kreislauferkrankungen , University Tübingen , Tübingen , Germany.
authors.forename: Fabian
authors.initials: F
authors.lastname: Stimpfle
authors.affiliation: a Medizinische Klinik III, Kardiologie und Kreislauferkrankungen , University Tübingen , Tübingen , Germany.
authors.forename: Oliver
authors.initials: O
authors.lastname: Borst
authors.affiliation: a Medizinische Klinik III, Kardiologie und Kreislauferkrankungen , University Tübingen , Tübingen , Germany.
authors.forename: Christine
authors.initials: C
authors.lastname: Zuern
authors.affiliation: a Medizinische Klinik III, Kardiologie und Kreislauferkrankungen , University Tübingen , Tübingen , Germany.
authors.forename: Sebastian
authors.initials: S
authors.lastname: Vogel
authors.affiliation: a Medizinische Klinik III, Kardiologie und Kreislauferkrankungen , University Tübingen , Tübingen , Germany.
authors.forename: Meinrad
authors.initials: M
authors.lastname: Gawaz
authors.affiliation: a Medizinische Klinik III, Kardiologie und Kreislauferkrankungen , University Tübingen , Tübingen , Germany.
authors.forename: Tobias
authors.initials: T
authors.lastname: Geisler
mesh_terms: D054058:Acute Coronary Syndrome / Q000175:diagnosis / Q000378:metabolism / Q000401:mortality / Q000628:therapy; D000368:Aged; D015415:Biomarkers; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism*; D002318:Cardiovascular Diseases / Q000175:diagnosis / Q000378:metabolism* / Q000401:mortality* / Q000628:therapy; D054377:Chemokine CXCL12 / Q000235:genetics / Q000378:metabolism*; D003324:Coronary Artery Disease / Q000175:diagnosis / Q000378:metabolism / Q000401:mortality / Q000628:therapy; D005260:Female; D005434:Flow Cytometry; D015870:Gene Expression; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008565:Membrane Proteins / Q000235:genetics / Q000378:metabolism*; D008875:Middle Aged; D063868:Patient Outcome Assessment; D062645:Percutaneous Coronary Intervention; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D011379:Prognosis; D012307:Risk Factors; D016277:Ventricular Function, Left
chemical_list: D015415:Biomarkers; D054377:Chemokine CXCL12; D008565:Membrane Proteins; D010975:Platelet Aggregation Inhibitors
keywords: Coronary artery disease; SDF-1; outcome; platelets